These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 24908933)

  • 1. [ASCO highlights in the treatment of metastatic melanoma].
    Hertlein A
    Med Monatsschr Pharm; 2014 May; 37(5):183-4. PubMed ID: 24908933
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.
    Sondak VK; Smalley K
    Pigment Cell Melanoma Res; 2009 Aug; 22(4):386-7. PubMed ID: 19624312
    [No Abstract]   [Full Text] [Related]  

  • 3. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance.
    Alcalá AM; Flaherty KT
    Clin Cancer Res; 2012 Jan; 18(1):33-9. PubMed ID: 22215904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinases as therapeutic targets in melanoma.
    Miller DM; Flaherty KT
    Pigment Cell Melanoma Res; 2014 May; 27(3):351-65. PubMed ID: 24405945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Melanoma].
    Uhara H
    Gan To Kagaku Ryoho; 2016 Apr; 43(4):404-7. PubMed ID: 27220785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel inhibitors in the treatment of metastatic melanoma.
    Kalinsky K; Haluska FG
    Expert Rev Anticancer Ther; 2007 May; 7(5):715-24. PubMed ID: 17492934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF inhibitors and melanoma.
    Flaherty KT
    Cancer J; 2011; 17(6):505-11. PubMed ID: 22157295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Raf inhibitors.
    McCubrey JA; Steelman LS; Abrams SL; Chappell WH; Russo S; Ove R; Milella M; Tafuri A; Lunghi P; Bonati A; Stivala F; Nicoletti F; Libra M; Martelli AM; Montalto G; Cervello M
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):633-48. PubMed ID: 19715444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment.
    Roukos DH; Papaloukas C; Tzaphlidou M
    Future Oncol; 2013 Jan; 9(1):5-8. PubMed ID: 23252557
    [No Abstract]   [Full Text] [Related]  

  • 13. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
    Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
    Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer research. Melanoma drug vindicates targeted approach.
    Garber K
    Science; 2009 Dec; 326(5960):1619. PubMed ID: 20019269
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma.
    Nickoloff BJ; Vande Woude G
    Pigment Cell Melanoma Res; 2012 Nov; 25(6):758-61. PubMed ID: 22974232
    [No Abstract]   [Full Text] [Related]  

  • 16. Narrative review: BRAF opens the door for therapeutic advances in melanoma.
    Flaherty KT
    Ann Intern Med; 2010 Nov; 153(9):587-91. PubMed ID: 21041578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
    Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
    Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting metastatic melanoma.
    Flaherty KT
    Annu Rev Med; 2012; 63():171-83. PubMed ID: 22034865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted treatment for melanoma.
    Monga M; Abraham J
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1113-5. PubMed ID: 23098110
    [No Abstract]   [Full Text] [Related]  

  • 20. Is there a role for single-agent BRAF inhibition in melanoma?
    Chmielowski B
    Clin Adv Hematol Oncol; 2017 Feb; 15(2):108-110. PubMed ID: 28398279
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.